Leap Therapeutics is a biopharmaceuticals firm that specializes in the treatment of cancer. Its lead program is the monoclonal antibody DKN-01, which is employed in multiple clinical trials for the treatment of several types of cancer. In addition, it has an option and license pact with BeiGene to create and sell DKN-01 in certain regions.